Full-Time

Senior Director

Global Commercial Content Ecosystem

Posted on 8/18/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

Compensation Overview

$151k - $314k/yr

Remote in USA

Remote

International travel of approximately 20% is required.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Veeva
Financial analysis
Data Modeling
Data Analysis

Get referred to Viatris

See people who can refer or advise you

Requirements
  • A bachelor's degree is required; an advanced degree is preferred.
  • At least 12 years of experience in content operations, business process, or digital content ecosystems is required.
  • Demonstrated leadership experience managing teams and enterprise platforms is required.
  • Deep experience with digital asset management, medical-legal-regulatory review, and/or content lifecycle platforms such as Veeva or Aprimo is required.
  • Strong experience in regulated environments is required; pharmaceutical experience is preferred.
  • Ability to operate at both strategic and operational levels is required.
  • Experience driving cross-functional alignment in complex, global organizations is required.
  • Strong partnership with information technology platform owners is required.
  • Strategic leadership with strong business and digital acumen is required.
  • An enterprise product mindset and value-driven decision-making ability are required.
  • Executive stakeholder engagement and influencing skills are required.
  • Strong understanding of content lifecycle, governance, and compliance is required.
  • A data-driven and analytical approach to performance management is required.
  • Ability to lead through complexity and drive organizational change is required.
  • Proficiency in speaking, comprehending, reading, and writing English is required.
Responsibilities
  • Create, define, and own the enterprise strategy and vision for the upstream content ecosystem, including medical-legal-regulatory review, digital asset management, content authoring tools, and integrations.
  • Develop infrastructure that enables modular content reuse and scalability, accelerated speed to market, regulatory compliance and audit readiness, and seamless user-centric experiences.
  • Establish digital asset management as the single source of truth and ensure ecosystem-wide alignment with end users.
  • Partner with senior leadership and cross-functional partners to align platform strategy with broader digital, marketing, and business objectives.
  • Develop and own the commercial roadmap for continuous improvement while balancing strategic transformation with operational priorities.
  • Define and track enterprise key performance indicators, including adoption and engagement, medical-legal-regulatory review cycle-time reduction, content reuse and efficiency gains, and reductions in manual processes and duplication.
  • Identify and prioritize innovation opportunities such as artificial-intelligence-enabled workflows, automation, and intelligent metadata.
  • Establish and enforce enterprise governance frameworks across platforms, including role-based capabilities and permissions, workflow standardization and controls, and metadata and taxonomy discipline.
  • Ensure platforms embed compliance by design and partner with Legal, Regulatory, and Compliance stakeholders to align with evolving requirements.
  • Manage the multi-year content ecosystem investment portfolio and roadmap for business requirements.
  • Develop business cases and value-realization strategies for platform enhancements and transformation initiatives.
  • Prioritize investments based on business value, risk reduction, compliance requirements, and strategic objectives.
  • Ensure realization of financial and operational benefits across the content ecosystem.
  • Maintain accountability for end-to-end platform performance across the ecosystem from a business perspective.
  • Monitor system adoption and utilization, workflow efficiency and bottlenecks, and metadata quality and integrity.
  • Lead a structured continuous-improvement program covering platform enhancements, process optimization, and integration maturity.
  • Translate insights into actionable improvements that deliver measurable business value.
  • Chair the enterprise content governance council and establish decision-making frameworks across stakeholders.
  • Serve as the final business escalation point for content ecosystem strategy, prioritization, and operating-model decisions.
  • Present strategic recommendations, roadmap decisions, and performance metrics to executive leadership.
  • Serve as the primary business stakeholder representing content operations requirements and priorities.
  • Partner with information technology to ensure scalable, secure, and stable platform architecture, effective translation of business requirements, and timely delivery of releases and enhancements.
  • Drive accountability across internal and external partners for performance and outcomes.
  • Lead and develop a team of business process owners and/or operational specialists.
  • Provide strategic direction and prioritization while delegating executional responsibilities.
  • Build organizational capability in platform utilization, content operations best practices, change management, and adoption.
  • Champion a product mindset across the team and broader organization.
  • Ensure alignment of platforms with enterprise metadata and taxonomy frameworks.
  • Oversee the integrity and flow of content and metadata across systems.
  • Enable robust reporting and analytics through structured, governed data.
  • Partner with the information technology team to evolve the content data model and integration strategy.
  • Travel internationally approximately 20%.
Desired Qualifications
  • An advanced degree is preferred.
  • Pharmaceutical experience in a regulated environment is preferred.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
  • Gross leverage fell to 2.9x after repaying roughly $900 million debt.
  • Fast-acting meloxicam has a December 27, 2026 FDA action date, supporting pipeline value.

What critics are saying

  • Tyvarya rights sale to Harrow shrinks growth assets and signals portfolio pruning.
  • Merck sitagliptin litigation still threatens U.S. generic launches through 2026 appeals.
  • EpiPen settlements keep Mylan-era pricing conduct alive, risking future antitrust liabilities.

What makes Viatris unique

  • Viatris spans branded, generic, and biosimilar medicines across 165 countries.
  • Greater China delivered 21% Q2 2026 growth through established brands and e-commerce.
  • FDA-approved Gwyn Lo and meloxicam add near-term proprietary launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.

Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.

PR Newswire
Aug 6th, 2026
Viatris reports Q2 revenues of $3.8B, up 5%, raises 2026 guidance despite $119M loss

Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.

Yahoo Finance
Aug 2nd, 2026
Viatris wins FDA approval for Gwyn Lo contraceptive patch

Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.

TipRanks
Jul 1st, 2026
Viatris secures $260M term loan facility to refinance debt and support operations

Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.